{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T13:29:49Z","timestamp":1774358989144,"version":"3.50.1"},"reference-count":26,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2020,2,8]],"date-time":"2020-02-08T00:00:00Z","timestamp":1581120000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA223662"],"award-info":[{"award-number":["R01CA223662"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["KL2TR002002"],"award-info":[{"award-number":["KL2TR002002"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R21HL140531"],"award-info":[{"award-number":["R21HL140531"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Intl Journal of Cancer"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:p>Several commonly used immune\u2010suppressing biologic drugs target proteins and cytokines involved in myeloma pathogenesis. Our objective was to determine whether targeted biologic disease\u2010modifying antirheumatic drugs (DMARDs) are associated with risk of multiple myeloma (MM). We conducted a nested case\u2013control study within a retrospective cohort of 56,886 commercially insured adults undergoing treatment for rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis between 2009 and 2015 using the Truven Health MarketScan Databases. MM cases (<jats:italic>n<\/jats:italic> =\u2009287) were matched to up to 10 controls (<jats:italic>n<\/jats:italic> =\u20092,760) on age, sex and rheumatologic indication using incidence density sampling without replacement. Our exposures of interest were biologic DMARDs targeting tumor necrosis factor\u2010alpha, interleukin 6, cytotoxic t\u2010lymphocyte\u2010associated protein\u20104 and depletion of B cells. Relative risks were estimated as adjusted odds ratios (OR) and 95% confidence intervals (CI) using conditional logistic regression models. Cases and controls were similar with respect to use of prescription NSAIDs and concurrent conventional\u2010synthetic DMARDs. Cases had slightly fewer etanercept users (4% <jats:italic>vs<\/jats:italic>. 7%) and slightly more tocilizumab users (1.4% <jats:italic>vs<\/jats:italic>. 0.4%). Compared to patients treated with only conventional\u2010synthetic DMARDs, those receiving concomitant conventional\u2010synthetic plus biologic DMARDs had lower risk of developing MM (OR = 0.48; 95% CI 0.30\u20130.88; <jats:italic>p<\/jats:italic> =\u20090.02). Risks differed by drug target with an inverse association observed with use of etanercept inhibiting tumor necrosis factor\u2010alpha (OR = 0.55; 95% CI 0.30\u20131.02; <jats:italic>p<\/jats:italic> =\u20090.06) and a positive association with tocilizumab inhibiting interleukin\u20106 (OR = 4.33; 95% CI 1.33\u201314.19; <jats:italic>p<\/jats:italic> =\u20090.02) compared to biologic DMARD\u2010na\u00efve patients. Further investigation is warranted to understand the roles of drugs suppressing tumor necrosis factor\u2010alpha and interleukin\u20106 in myeloma pathogenesis.<\/jats:p>","DOI":"10.1002\/ijc.32891","type":"journal-article","created":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T09:27:04Z","timestamp":1580376424000},"page":"1300-1305","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Targets of biologic disease\u2010modifying antirheumatic drugs and risk of multiple myeloma"],"prefix":"10.1002","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7744-3518","authenticated-orcid":false,"given":"Gregory S.","family":"Calip","sequence":"first","affiliation":[{"name":"Department of Pharmacy Systems, Outcomes and Policy University of Illinois at Chicago  Chicago IL"},{"name":"Center for Pharmacoepidemiology and Pharmacoeconomic Research University of Illinois at Chicago  Chicago IL"},{"name":"Division of Public Health Sciences, Fred Hutchinson Cancer Research Center  Seattle WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pritesh R.","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology University of Illinois at Chicago  Chicago IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Sweiss","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice University of Illinois at Chicago  Chicago IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaoju","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Systems, Outcomes and Policy University of Illinois at Chicago  Chicago IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jifang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Systems, Outcomes and Policy University of Illinois at Chicago  Chicago IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alemseged A.","family":"Asfaw","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Systems, Outcomes and Policy University of Illinois at Chicago  Chicago IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sruthi","family":"Adimadhyam","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Systems, Outcomes and Policy University of Illinois at Chicago  Chicago IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd A.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Systems, Outcomes and Policy University of Illinois at Chicago  Chicago IL"},{"name":"Center for Pharmacoepidemiology and Pharmacoeconomic Research University of Illinois at Chicago  Chicago IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian C.\u2010H.","family":"Chiu","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences The University of Chicago  Chicago IL"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,2,8]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-13-0695"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0091461"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210715"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1745-7254.2008.00889.x"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204623"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.197"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-692954"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-554071"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.07.010"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.174482"},{"key":"e_1_2_9_12_1","volume-title":"FDA Drug Safety Communication: Safety Review update on reports of Hepatosplenic T\u2010Cell Lymphoma in adolescents and young adults receiving tumor necrosis factor (TNF) blockers, azathioprine and\/or mercaptopurine","author":"US Food and Drug Administration","year":"2011"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.295.19.2275"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.149419"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31407"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209389"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(92)90133-8"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.03.075"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0000000000000221"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-5-5"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/25.6.1107"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncprheum0761"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.50.4636"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar565"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp070449"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.19.7547"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205847"}],"container-title":["International Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fijc.32891","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.32891","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ijc.32891","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ijc.32891","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T10:24:22Z","timestamp":1693736662000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ijc.32891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,8]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1002\/ijc.32891"],"URL":"https:\/\/doi.org\/10.1002\/ijc.32891","archive":["Portico"],"relation":{},"ISSN":["0020-7136","1097-0215"],"issn-type":[{"value":"0020-7136","type":"print"},{"value":"1097-0215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,8]]},"assertion":[{"value":"2019-07-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}